Tyanna N. Hadley
FDA investigator
Appears on 3 documents from 2022 to 2024, mostly at sites in New Jersey. Most often cites postmarketing reporting of adverse drug experiences (21 CFR 314.80(b)).
- 3
- Documents on file
- 2.3
- Observations per 483
- 2022
- First seen
- 2024
- Most recent
What they cite most
From 7 observations- 21 CFR 314.80(b)Postmarketing reporting of adverse drug experiences2
- FDCA 505-1(f)(4)2
- FDCA 505-1(f)(3)(A)1
- FDCA 505-1(f)(3)(B)1
- FDCA 505-1(f)(3)(E)1
Activity by year
2022: 1, 2024: 2
Where
New Jersey 2 · New York 1
Is Tyanna N. Hadley coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
3 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2024-12-06 | 483 CELGENE CORPORATIONDec 6, 2024 · SUMMIT, New Jersey | SUMMIT, New Jersey | 4 | |
| 2024-03-11 | 483 APPCO PHARMA LLCMar 11, 2024 · Piscataway, New Jersey | Piscataway, New Jersey | 2 | |
| 2022-09-15 | 483 Ascent Pharmaceuticals IncSep 15, 2022 · Central Islip, New York | Central Islip, New York | 1 |
About this profile
What does Tyanna N. Hadley inspect?
Tyanna N. Hadley appears on 3 documents on file covering 3 sites, mostly in New Jersey.
What do they cite most often?
21 CFR 314.80(b) (postmarketing reporting of adverse drug experiences), followed by FDCA 505-1(f)(4) and FDCA 505-1(f)(3)(A).
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Tyanna N. Hadley is dated Dec 6, 2024.